Abstracts tagged "Biologics"

Abstract Number: 2881 • 2019 ACR/ARP Annual Meeting
Dual Neutralization of IL-17A and IL-17F with Bimekizumab in Patients with Active Psoriatic Arthritis: Disease Activity and Remission in a 48-Week Phase 2b, Randomized, Double‑Blind, Placebo-Controlled, Dose-Ranging Study
Philip Mease¹, Laure Gossec ², Laura Coates ³, Alice B. Gottlieb ⁴, Deepak Assudani ⁵, Barbara Ink ⁵, Jason Coarse ⁶, Oscar Irvin-Sellers ⁵ and Dafna Gladman ⁷, ¹Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA, ²Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France, ³University of Oxford, Oxford, United Kingdom, ⁴Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA, Philadelphia, PA, ⁵UCB Pharma, Slough, UK, Slough, United Kingdom, ⁶UCB Pharma, Raleigh, NC, USA, Raleigh, NC, ⁷Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada
Background/Purpose: The ultimate goal of therapy in patients with psoriatic arthritis (PsA) is clinical remission, defined as ‘the absence of clinical and laboratory evidence of…
Abstract Number: 849 • 2019 ACR/ARP Annual Meeting
Risk of Malignancies Associated with Biologics in Rheumatoid Arthritis: Analysis of a National Claim Database
Raphaèle Seror¹, Alexandre Lafourcade ², yann De Rycke ², Bruno Fautrel ³, Xavier Mariette ⁴ and Florence Tubach ⁵, ¹Université Paris Sud, Hôpitaux Universitaires Paris-Sud, AP-HP, INSERM UMR 1184, Le Kremlin-Bicêtre, France, ²Biostatistics, Public Health and Medical Information department, Pitié-Salpêtrière Hospital, AP-HP, Paris, France, Paris, France, ³Pitié-Salpêtrière Hospital, Department of Rheumatology, AP-HP, Sorbonne University, UPMC university, Paris, Ile-de-France, France, ⁴Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France, ⁵Pitié Salpétrière University-Hospital, Paris, Ile-de-France, France
Background/Purpose: Our objectives were to estimate and compare the incidence rate of malignancies between biologic and csDMARD-treated RA patients.Methods: We conducted an historical cohort study…
Abstract Number: 2097 • 2019 ACR/ARP Annual Meeting
Tuberculin Skin Test and Quantiferon®-TB Gold In-Tube Test for Latent Tuberculosis Before Biologic Treatments: Lower Agreement Rate in Spondyloarthropathies Compared to Rheumatoid Arthritis
Ufuk İlgen¹, Sezin Turan ¹, Hakan Emmungil ¹, Alper Sarı ², Abdulsamet Erden ², Levent Kilic ³, Ömer Karadağ ², Sedat Kiraz ³, Ali İhsan Ertenli ⁴, Orhan Küçükşahin ⁵, Şükran Erten ⁶, Zeynel Abidin Akar ⁷, Burak Öz ⁷, Süleyman Serdar Koca ⁸, Cemal Bes ⁹, Nilufer Alpay-Kanitez ¹⁰, Emre Tekgöz ¹¹, Seda Çolak ¹¹, Muhammet Çınar ¹¹, Sedat Yılmaz ¹¹, Veli Yazısız ¹², Mustafa Ender Terzioğlu ¹², Ayşe Bahar Keleşoğlu Dinçer ¹³, Aşkın Ateş ¹³, Rıdvan Mercan ¹⁴, Onay Gercik ¹⁵, Servet Akar ¹⁶, Mehmet Pamir Atagündüz ¹⁷, Gezmiş Kimyon ¹⁸, Emel Gönüllü ¹⁹, Emine Duygu Ersözlü ²⁰, Müge Aydın Tufan ²¹, Burcu Yağız ²², Belkıs Nihan Coşkun ²³, Yavuz Pehlivan ²², Ediz Dalkılıç ²² and Umut Kalyoncu ²⁴, ¹Trakya University, Edirne, Turkey, ²Hacettepe University, Ankara, Turkey, ³Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ⁴Hacettepe University Vasculitis Centre, Ankara, Turkey, Ankara, Turkey, ⁵Liv Hospital, Ankara, Turkey, ⁶Yıldırım Beyazıt University, Ankara, Turkey, ⁷Fırat University, Elazığ, Turkey, ⁸Fırat University School of Medicine Division of Rheumatology, Elazığ, Turkey, ⁹University of Medical Sciences, İstanbul, Turkey, ¹⁰Koc University School of Medicine, Division of Rheumatology, İstanbul, Turkey, ¹¹University of Medical Sciences, Ankara, Turkey, ¹²Akdeniz University, Antalya, Turkey, ¹³Ankara University, Ankara, Turkey, ¹⁴Namık Kemal University, Tekirdağ, Turkey, ¹⁵Izmir Katip Celebi University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, İzmir, Turkey, ¹⁶Izmir Katip Celebi University, Faculty of Medicine, Division of Rheumatology, İzmir, Turkey, ¹⁷Marmara University, İstanbul, Turkey, ¹⁸Mustafa Kemal University, Hatay, Turkey, ¹⁹Sakarya University, Sakarya, Turkey, ²⁰Adana State Hospital, Adana, Turkey, ²¹Başkent University, Adana, Turkey, ²²Uludağ University, Bursa, Turkey, ²³Uludağ University, Bursa, ²⁴Hacettepe University Department of Rheumatology, Ankara, Turkey
Background/Purpose: Screening for and the treatment of latent tuberculosis is recommended in patients with inflammatory arthritides prior to biologic treatments, particularly the TNF inhibitors. The…
Abstract Number: 894 • 2019 ACR/ARP Annual Meeting
Frequency, Severity and Costs of Flares Increase with Disease Severity in Newly Diagnosed Systematic Lupus Erythematous: A Real-World Cohort Study, United States, 2004–2015
Miao Jiang ¹, Barnabas Desta ¹, Aimee Near ², Xia Wang ¹ and Edward Hammond¹, ¹AstraZeneca, Gaithersburg, MD, ²IQVIA, Durham, NC
Background/Purpose: We evaluated the real-world frequency and severity of flares and associated costs 1 year post diagnosis in a US cohort with newly diagnosed SLE.Methods:…
Abstract Number: 2253 • 2019 ACR/ARP Annual Meeting
Comparing Patient and Provider Perspectives on Long Term Biologic Use and Tapering in Stable, Well-Controlled Rheumatoid Arthritis
Patrick Webster¹, Nicole Wilson ², Christina Payne ¹, Kelly Shields ³ and Tarun Sharma ¹, ¹Allegheny Health Network, Pittsburgh, PA, ²Medicine Institute Research, Bioinformatics, Pittsburgh, PA, ³Highmark Data Science, Pittsburgh
Background/Purpose: The 2015 American College of Rheumatology (ACR) and 2013 European League Against Rheumatology (EULAR) guidelines for management of rheumatoid arthritis (RA) conditionally recommend consideration…
Abstract Number: 937 • 2019 ACR/ARP Annual Meeting
Dual Neutralization of IL-17A and IL-17F with Bimekizumab in Patients with Active Ankylosing Spondylitis: 48-Week Efficacy and Safety Results from a Phase 2b, Randomized, Blinded, Placebo-Controlled, Dose-Ranging Study
Désirée van der Heijde¹, Lianne Gensler ², Atul Deodhar ³, Xenofon Baraliakos ⁴, Denis Poddubnyy ⁵, Alan Kivitz ⁶, Marga Oortgiesen ⁷, Dominique Baeten ⁸, Nadine Goldammer ⁹, Jason Coarse ⁷, MK Farmer ⁷ and Maxime Dougados ¹⁰, ¹Leiden University Medical Center, Leiden, Netherlands, ²University San Francisco California, San Francisco, CA, ³Oregon Health & Science University, Portland, OR, ⁴Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, Herne, Germany, ⁵Charité - Universitätsmedizin Berlin and German Rheumatism Research Centre, Berlin, Germany, Berlin, Germany, ⁶Altoona Center for Clinical Research, Duncansville, PA, ⁷UCB Pharma, Raleigh, NC, USA, Raleigh, NC, ⁸UCB Pharma, Brussels, Belgium, Brussels, ⁹UCB Pharma, Monheim, Germany, Monheim, Germany, ¹⁰Cochin Hospital, Paris, France
Background/Purpose: The monoclonal antibody bimekizumab potently and selectively neutralizes both IL-17A and IL-17F. We report the 48-week efficacy and safety of bimekizumab in patients (pts)…
Abstract Number: 2340 • 2019 ACR/ARP Annual Meeting
Treatment of Interstitial Lung Disease and Airway Disease Complicated with Rheumatoid Arthritis
Takeshi Shoda¹, Tohru Takeuchi ², Takuya Kotani ², Koji Nagai ², Kennichiro Hata ², Shigeki Makino ² and Shigeki Arawaka ², ¹Yodogawa christian hospital / Osaka medical college, Osaka, Japan, ²Osaka medical college, Osaka, Japan
Background/Purpose: Interstitial lung disease (ILD) complicated with rheumatoid arthritis (RA) is detected in 27 to 67% of patients on high-resolution computed tomography (HRCT), and airway…
Abstract Number: 1381 • 2019 ACR/ARP Annual Meeting
High Serum IgA and High Proportion of Activated Th17 and Activated Treg Cells Are Predictive Biomarkers for Remission Achievement with Abatacept in Patients with Early, Seropositive Rheumatoid Arthritis
Jun Inamo¹, Yuko Kaneko ², Jun Kikuchi ³ and Tsutomu Takeuchi ⁴, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Tokyo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku, Tokyo, Japan, ³Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, ⁴Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Abatacept (ABT) is a soluble fusion protein, which links cytotoxic T-lymphocyte-associated protein 4 to the modified Fc portion of IgG1. Seropositivity and a shorter…
Abstract Number: 2346 • 2019 ACR/ARP Annual Meeting
Interstitial Lung Abnormalities in Rheumatoid Arthritis Patients: Identifying Associated Risk Factors
Karina Bonfiglioli¹, Márcio Sawamura ², Renato Nakagawa ³, Fábio Arimura ³, Diana Rangel ³, Cleonice Bueno ⁴, Ana Cristina de Medeiros Ribeiro ¹, Carlos Carvalho ³, Eloisa Bonfa ⁵, Ronaldo Kairalla ³ and Leticia Kawano-Dourado ⁶, ¹Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Sao Paulo, Brazil, ²Division of Radiology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Br, Sao Paulo, Sao Paulo, Brazil, ³Pulmonary Division, Heart Institute (InCor)- Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR, Sao Paulo, Sao Paulo, Brazil, ⁴Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR, Sao Paulo, Sao Paulo, Brazil, ⁵Rheumatology Division, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil., Sao Paulo, Sao Paulo, Brazil, ⁶University of Sao Paulo, Sao Paulo, Brazil
Background/Purpose: A wide spectrum of interstitial lung abnormalities (ILA) occurs in patients with rheumatoid arthritis (RA). This study characterized ILA in large single-center cohort, including…
Abstract Number: 1399 • 2019 ACR/ARP Annual Meeting
Evaluation of Effectiveness and Usage Patterns of Tofacitinib in Treatment of Rheumatoid Arthritis in Australia: An Analysis from the OPAL-QUMI Real World Dataset
Paul Bird¹, Geoffrey Littlejohn ², Belinda Butcher ³, Tegan Smith ⁴, Candida da Fonseca Pereira ⁵, David Witcombe ⁵ and Hedley Griffiths ⁶, ¹Optimus Research, Kogarah, New South Wales, Australia, ²Monash Rheumatology, Clayton, Victoria, Australia, ³WriteSource Medical Pty Ltd, Lane Cove, New South Wales, Australia, ⁴OPAL Rheumatology Ltd, Sydney, New South Wales, Australia, ⁵Pfizer Australia, Sydney, New South Wales, Australia, ⁶Barwon Rheumatology Service, Geelong, Victoria, Australia
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Limited data from large real-world patient populations exist to describe…
Abstract Number: 2371 • 2019 ACR/ARP Annual Meeting
Risk of Malignancies Across Biologic Classes in Rheumatoid Arthritis: Analysis of a National Claim Database
Raphaèle Seror¹, Alexandre Lafourcade ², yann De Rycke ², Bruno Fautrel ³, Xavier Mariette ⁴ and Florence Tubach ⁵, ¹Université Paris Sud, Hôpitaux Universitaires Paris-Sud, AP-HP, INSERM UMR 1184, Le Kremlin-Bicêtre, France, ²Biostatistics, Public Health and Medical Information department, Pitié-Salpêtrière Hospital, AP-HP, Paris, France, Paris, France, ³Pitié-Salpêtrière Hospital, Department of Rheumatology, AP-HP, Sorbonne University, UPMC university, Paris, Ile-de-France, France, ⁴Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France, ⁵Pitié Salpétrière University-Hospital, Paris, Ile-de-France, France
Background/Purpose: Our objectives were to estimate and compare the incidence rate of malignancies associated with the different classes of biologics in RA patients.Methods: We conducted…
Abstract Number: 1476 • 2019 ACR/ARP Annual Meeting
Impact of Alternate Mechanism of Action Biologics and Tofacitinib on TNF-α Inhibitor Prescribing in Psoriatic Arthritis: Results from Annual National Patient Chart Audits
Lynn Price¹, Phil Pouliot ¹ and Lauren Schmitt ¹, ¹Spherix Global Insights, Exton, PA
Background/Purpose: TNF-α inhibitor therapy has long been the standard of care for adult patients diagnosed with moderate to severe psoriatic arthritis (PsA), though several new…
Abstract Number: 2372 • 2019 ACR/ARP Annual Meeting
Post-Approval Comparative Safety Study of Tofacitinib and Biologic DMARDs: Five‑Year Results from a US-based Rheumatoid Arthritis Registry
Joel Kremer¹, Clifton Bingham ², Laura Cappelli ², Jeffrey Greenberg ³, Jamie Geier ⁴, Ann Madsen ⁴, Connie Chen ⁴, Alina Onofrei ⁵, Christine Barr ⁵, Dimitrios Pappas ⁶, Heather Litman ⁵, Kimberly Dandreo ⁵, Andrea Shapiro ⁷, Carol Connell ⁸ and Arthur Kavanaugh ⁹, ¹Albany Medical College, Albany, NY, ²Johns Hopkins University, Baltimore, MD, ³Corrona, LLC; NYU School of Medicine, Waltham, MA, ⁴Pfizer Inc, New York, NY, ⁵Corrona, LLC, Waltham, MA, ⁶Columbia University, New York, NY, ⁷Pfizer Inc, Peapack, NJ, ⁸Pfizer Inc, Groton, CT, ⁹University of California, San Diego School of Medicine, La Jolla, CA
Background/Purpose: Tofacitinib is an oral JAK inhibitor for the treatment of RA. Real‑world data (RWD) complement clinical trial data in assessing long-term safety. We evaluated…
Abstract Number: L12 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: 16 Week Results of a Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial in Patients with Prior Inadequate Response or Intolerance to 1 or 2 Tumor Necrosis Factor Inhibitors
Atul A. Deodhar¹, Denis Poddubnyy², Cesar Pacheco-Tena³, Carlo Salvarani⁴, Eric Lespessailles⁵, Proton Rahman⁶, Pentti Järvinen⁷, Juan Sanchez-Burson⁸, Karl Gaffney⁹, Eun Bong Lee¹⁰, Eswar Krishnan¹¹, Silvia Santisteban¹¹, Xiaoqi Li¹¹, Fangyi Zhao¹¹, Hilde Carlier¹¹ and John D. Reveille¹², ¹Oregon Health & Science University, Portland, Portland, OR, ²Rheumatology, Campus Benjamin Franklin Charité – Universitätsmedizin, Germany and German Rheumatism Research Centre, Berlin, Germany, Berlin, Germany, ³Facultad de Medicina, Universidad Autónoma de Chihuahua, Chihuahua, Mexico, ⁴Azienda USL-IRCCS di Reggio Emilia and Universita’ di Modena e Reggio Emilia, Reggio Emilia, Italy, ⁵Rheumatology, CHR Orléans and University of Orléans, Orléans, France, ⁶Medicine, Memorial University, St John's, NF, Canada, ⁷Rheumatology, Kiljava Medical Research, Hyvinkää, Finland, ⁸Hospital Infanta Luisa, Sevilla, Spain, ⁹Rheumatology, Norfolk and Norwich University Hospital NHS Foundation Trust and Norwich Medical School, University of East Anglia, Norwich, United Kingdom, ¹⁰Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic of (South), ¹¹Eli Lilly and Company, Indianapolis, IN, ¹²Rheumatology, McGovern Medical School at the University of Texas Health Science Center at Houston, USA, Houston, TX
Background/Purpose: TNF inhibitors (TNFi) are recommended for patients with axial SpA (axSpA) who do not respond to or tolerate NSAIDs. Some patients are inadequate responders…
Abstract Number: 286 • 2018 ACR/ARHP Annual Meeting
The Prevalence and Treatment Patterns of Women of Childbearing Age with Rheumatic Diseases
Edward Lee¹, Robert Suruki², Brian Carpenter³, Ty Harkness³, Daniel Luk⁴ and Mohamed Yassine¹, ¹UCB Pharma, Smyrna, GA, ²UCB Pharma, Raleigh, NC, ³Charles River Associates, New York, NY, ⁴Charles River Associates, Boston, MA
Background/Purpose: Emerging data on exposure of infants to therapeutics through placental transfer and breastmilk could impact the management of women of childbearing age (WoCBA) with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].